PhenomeX Inc.

Good day, everyone, and welcome to the Phenomex First Quarter 2023 Earnings Call. Today's call is being recorded. I would now like to turn the conference over to Suzanne Hatcher, Senior Vice President, Investor Relations and Communications. Please go ahead.

Thank you, Operator. Good afternoon, everyone, and welcome to the Phenomex First Quarter 2023 Earnings Call reporting financial results for the quarter ended March 31, 2023. My name is Suzanne Hatcher, Senior Vice President of Communications and Investor Relations at Finomex. I'm joined today by Dr. Siddhartha Kadia, Chief Executive Officer, Mehul Joshi, Chief Financial Officer, and Dr. Rolando Brower, Chief Business Officer. Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking statements within the meaning of federal security laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. For more information, please refer to the risks, uncertainties, and other factors discussed in our SEC filings. Except as required by law, Phenome X disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. This conference call contains time-sensitive information and is accurate only as a live broadcast

may 11 2023 as a reminder you can find today's press release and an investor presentation on the phenomex website under the investor relations section with that i would like to turn the call over to sadartha thanks suzanne and thank you everyone for joining us for our first earning call as phenomex at the end of first quarter we completed the acquisition of isoflexis forming the combined company called Phenomax. As Phenomax, we are positioned to be the leading provider of life sciences solutions that will have the greatest impact advancing the era of the phenome as the next revolution in biology and medicine unfolds. Our unique suite of products and services offer unprecedented resolution and speed. In fact, Phenomax serves the only single cell platform able to isolate manipulate and characterize live cells while enabling large-scale and multiplexed functional multi-omics. Our mission is to empower scientists to leverage the full potential of each cell and drive the next era of functional cell biology that will advance human health. We now have an installed base of 430 platforms with placements in all top 15 pharma companies by revenue and approximately 85% of United States comprehensive cancer centers. Our products have been cited in over 225 publications and are supported by a robust intellectual property portfolio of more than 600 patents. I will begin the call today by providing updates on the tremendous integration progress we have made in just seven weeks since the closing of the IsoPlexus acquisition and the tangible actions we are taking as we continue to execute on the five pillars of our strategic operating plan. I will then turn the call over to Mehul who will discuss our first quarter results and full year 2023 financial guidance. Starting with our first strategic pillar of building a world-class life sciences leadership team, we are continuing to bring on industry leaders with a proven track record in scaling life sciences tools companies. At the end of March, Dr. Yan Zhang joined Phenomax as Chief Commercial Officer. In this newly created position, Yann oversees our global commercial organization and helps drive strategic growth across our platform and services business. Yann brings over 25 years of operating and management experience in the life sciences tools industry. Most recently, she served as CEO at MissionBio, a life sciences company focused on high-throughput single-cell DNA and multi-omics analysis. Before MissionBio, Yan served in various commercial and business executive leadership roles at Thermo Fisher Scientific, Life Technologies, FEMetrics, NewGen Technologies, and Molecular Devices. With the addition of Jan, we have a strong operational team in place with Sean McKay, Chief Product Officer and former CEO of IsoPlexus, Eric Hobbs, Head of Global Operations and Business Integration and former Chief Executive Officer of Berkeley Lights, and Rolando Brower, who in his role as Chief Business Officer leads the research and development, and business development teams, and is a former executive from Thermo Fisher Scientific, Exact Sciences, and Danaher. Our goal of building out the leadership team with deep experience in life sciences tools space is now complete. I believe PhenomX collectively has the bench strength in life sciences tools as well as corporate function expertise in finance, human resources, legal and communications that is needed to become the platform for growth in the life sciences tool space. We look forward to building momentum in critical global markets with our technology and unlocking the new company's tremendous potential. Moving on to our second strategic pillar of prioritizing R&D return on investment through increased focus and rigor on development initiatives. When forming PhenomX, one of our main objectives was to create a balanced product portfolio with a range of price points to provide broader customer access across a larger portion of the cell biology market. To achieve this, we are focused on three key near-term development objectives. Number one, growing the core business in antibody discovery, cell line development, and single-cell and bulk proteomics within three market segments, discovery, bioprocessing, and translational and clinical research. Number two, completing the inducible producer cell line, IPCL, selector application for our latest system in development. This Beacon gene therapy system, which will be branded Beacon X, is expected to deliver unparalleled speed in cell line development within the AAV gene therapy space. And number three, unlocking a new market in single-cell functional multiomics for T-cells with the recent launch of the T-cell profiling workflow on Beacon and BeaconQuest for immuno-oncology and cell therapy serving both academic and industrial market segments.